Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01515969 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Patient safety - Unacceptable toxicity

Conditions

Non-small Cell Lung Cancer (NSCLC), Recurrent
Non-small Cell Lung Cancer (NSCLC), Stage IV

Interventions

DRUG: Erlotinib hydrochloride
DRUG: Dovitinib lactate

Sponsor

Heather Wakelee

Collaborators

[object Object]
[object Object]